Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Gabriella McCarty

NP-C

Gabriella McCarty is a gastroenterology/hepatology nurse practitioner. She obtained her masters and nurse practitioner degree at Case Western Reserve University in 2004. She has been practicing in this field for 26 years. She serves as faculty for Gastroenterology/ Hepatology Advanced Practice Providers (GHAPP) and is an American College of Gastroenterology (ACG) committee member, serving on the education subcommittee. She will be completing her doctorate of nursing in May 2025. She loves all aspects of GI / Hepatology, education and nursing.

play

Alison Moe

PA-C

Alison S. Moe, MS, PA-C, is a board-certified physician assistant specializing in gastroenterology at United Digestive's Braselton office in Hoschton, Georgia. She earned her Master of Science in Medical Education from Seton Hall University and a Bachelor of Arts in Physical Anthropology from the State University of New York at Stony Brook. Alison is fluent in Spanish and has a special interest in treating irritable bowel syndrome and liver disease. With almost two decades of experience as a Physician Assistant, Alison has developed a strong foundation in both clinical practice and research, particularly in the fields of gastroenterology and hepatology. Alison's dedication to patient care includes extensive clinical hours, allowing her to cultivate deep relationships with patients as well as national experts caring for individuals, especially those suffering from inflammatory bowel disease (IBD) and advanced liver disease. Alison's commitment to advancing the understanding and treatment of these conditions drives my clinical practice and ongoing research efforts, aiming to provide the highest standard of care for my patients.

play

Christie Morrison

AGACNP-BC

Christie Morrison is a Board Certified Adult Advanced Practice Nurse and Lead APP at Oshi Health, a digital digestive health practice and IBD APP at Texas Digestive Disease Consultants in San Antonio, Texas. She strives to improve the lives of patients with chronic gastrointestinal conditions through a multidisciplinary approach. She has worked in various roles as a GI advanced practice provider, including inpatient, outpatient clinic, and telehealth since 2015. Mrs. Morrison is currently an active member of the American College of Gastroenterology where she is serving on the Editorial Board. She is also a member of several GI societies, including TSGE, AGA, ASGE, and GHAPP. Christie was recently honored with the ACG APP Clinical Excellence Award for community practice. She collaborates with industry partners and GI colleagues to enhance education and engagement for APPs working in Gastroenterology. She strives to improve the quality of life and better patient outcomes in all chronic GI conditions and believes that providing resources to her peers through education can help her achieve this goal.

MASLD/MASH Learning Center

Latest News & Blogs

A novel multi-parameter MRI-based model for identification of high-risk metabolic dysfunction-associated steatohepatitis

August 2025

CONCLUSION: The novel EFT1 model demonstrates reasonable performance in non-invasive identification of high-risk MASH patients compared to other models, achieving an appropriate balance between sensitivity and specificity.

Read More arrow

Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis

August 2025

Increased mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) imposes an urgent need to elucidate the pathogenesis of MASLD so that novel therapeutic strategies may be identified. Here, we delineate the mechanism of microRNA-34a-5p (miR-34a) in the progressive liver injury of MASLD and liver fibrosis. Specifically, liver tissue from patients with obesity-associated hepatic steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and fibrosis, as...

Read More arrow

MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians

August 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a significant public health issue worldwide, with a pronounced impact in India due to the escalating rates of obesity and type 2 diabetes mellitus (T2DM) driving its prevalence. This condition spans a range of hepatic disorders, from uncomplicated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), accompanied by differing levels of hepatic...

Read More arrow

Celastrol ameliorates metabolic dysfunction associated steatohepatitis by regulating the CYP7B1-mediated alternative bile acid synthetic pathway

August 2025

CONCLUSION: Our study demonstrated CEL as a novel MASH therapeutic that uniquely targets the FXR/LXR-CYP7B1 axis to reactivate the alternative BA synthetic pathway, providing a mechanistic basis for CEL in MASH intervention.

Read More arrow

Mechanism of Lipi Jiangzhuo Decoction in Improving Metabolic Dysfunction-Associated Steatohepatitis Through the PERK/PINK1/GPx4 Pathway

August 2025

CONCLUSION: LPJZD can improve MASH by regulating ER stress-mitophagy -ferroptosis axis in liver cells. The role of LPJZD in anti-inflammatory therapy provides new insights for the clinical prevention and treatment of MASH.

Read More arrow

More Than Just Bone Pain: A Case of Paget's Disease, Seropositive Rheumatoid Arthritis, and Metabolic Dysfunction-Associated Steatohepatitis (MASH) in a Patient With Elevated Alkaline Phosphatase (ALP)

August 2025

Paget's disease of bone is a chronic skeletal disorder characterized by disorganized bone remodeling. Although often asymptomatic, it is frequently first detected through elevated alkaline phosphatase (ALP). Given ALP's nonspecific nature, its elevation requires a comprehensive evaluation for hepatic, biliary, and bone pathology. We present a diagnostic challenge involving persistent ALP elevation in a patient ultimately found to have coexisting Paget's disease, metabolic dysfunction-associated...

Read More arrow

Identification of foam cell like M2 macrophages, AEBP1 biomarkers, and resveratrol as potential therapeutic in MASLD using Ecotyper and WGCNA

August 2025

The immune cell landscapes in metabolic dysfunction-associated fatty liver disease (MAFLD) and their clinical relevance have not been explored. We used Ecotyper to identify immune cell states based on gene expression and examined their roles in metabolic dysfunction-associated steatotic liver disease (MASLD) progression. Limma was applied to identify differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) was used for module identification. Bidirectional...

Read More arrow

miR-210-3p Ameliorates Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis by Targeting ISCU and Induces Ferroptosis

August 2025

CONCLUSIONS: miR-210-3p expression is decreased in MASH-related fibrosis and is involved in ferroptosis by targeting ISCU.

Read More arrow

Insights Into Intestinal Flora in Metabolic Dysfunction-Associated Steatotic Liver Disease

August 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic disease characterized by excessive accumulation of liver fat, encompassing nonalcoholic fatty liver (NAFL) and metabolic dysfunction-associated steatohepatitis (MASH), which is among the rapidly proliferating diseases globally. MASLD disrupts the normal structure and function of the liver, resulting in liver fibrosis, cirrhosis, and ultimately hepatocellular cancer and other severe outcomes. Recent investigations...

Read More arrow

ISG15 deficiency in hepatic stellate cells promotes TGFbeta2-induced liver fibrosis by counteracting CREB1 ISGylation

August 2025

CONCLUSIONS: ISG15 regulated HSC activation and liver fibrosis in part via the CREB1/TGFβ2/SMAD2 regulatory pathway. Utilisation of ISG15-CREB1 signalling may be a potential therapeutic target for liver fibrosis.

Read More arrow

Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

August 2025

BACKGROUND: Efruxifermin is a bivalent fibroblast growth factor 21 analogue in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to prospectively assess the safety and efficacy of efruxifermin administration for 96 weeks in individuals with MASH and moderate (stage 2; F2) or severe (stage 3; F3) fibrosis.

Read More arrow

CuSO<sub>4</sub> protects hepatocytes from lipotoxicity by promoting autophagic degradation of lipid droplets to attenuate oxidative stress

August 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a prevalent chronic liver condition that often progresses to Metabolic Dysfunction-Associated Steatohepatitis (MASH), ultimately leading to liver fibrosis and hepatocellular carcinoma (HCC). Consequently, the early diagnosis and treatment of MASLD are particularly crucial. Currently, the pathogenic mechanisms underlying MASLD remain incompletely understood, and there is no optimal therapy available for this condition. The liver...

Read More arrow

The peroxisome proliferator-activated receptor alpha/beta/gamma agonist NCPC-626 from microbial metabolites alleviates metabolic dysfunction-associated steatohepatitis in mice

August 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease characterized by steatosis, inflammatory responses, and fibrosis. Peroxisome proliferator-activated receptors (PPARs), master regulators of glucolipid homeostasis and inflammatory pathways, have emerged as promising therapeutic targets for MASH. PPAR agonists have demonstrated therapeutic potential in MASH by ameliorating hepatic lipid deposition, normalizing dyslipidemia, enhancing insulin sensitivity, and...

Read More arrow

Fibroblast growth factor 15 overexpression and combined peroxisome proliferator-activated receptor alpha activation attenuates metabolic dysfunction-associated steatohepatitis progression in mice

August 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is increasing worldwide along with the obesity epidemic. However, there are limited treatments. Fibroblast growth factor (FGF)19 and its mouse ortholog FGF15, act as hormones to repress bile acid synthesis and increase energy expenditure. Activation of peroxisome proliferator-activated receptor (PPAR)α increases fatty acid oxidation in hepatocytes. However, a combined role of FGF19/15 with activation of PPARα in the treatment of MASH is...

Read More arrow

CuSO<sub>4</sub> protects hepatocytes from lipotoxicity by promoting autophagic degradation of lipid droplets to attenuate oxidative stress

August 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a prevalent chronic liver condition that often progresses to Metabolic Dysfunction-Associated Steatohepatitis (MASH), ultimately leading to liver fibrosis and hepatocellular carcinoma (HCC). Consequently, the early diagnosis and treatment of MASLD are particularly crucial. Currently, the pathogenic mechanisms underlying MASLD remain incompletely understood, and there is no optimal therapy available for this condition. The liver...

Read More arrow

CuSO<sub>4</sub> protects hepatocytes from lipotoxicity by promoting autophagic degradation of lipid droplets to attenuate oxidative stress

August 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a prevalent chronic liver condition that often progresses to Metabolic Dysfunction-Associated Steatohepatitis (MASH), ultimately leading to liver fibrosis and hepatocellular carcinoma (HCC). Consequently, the early diagnosis and treatment of MASLD are particularly crucial. Currently, the pathogenic mechanisms underlying MASLD remain incompletely understood, and there is no optimal therapy available for this condition. The liver...

Read More arrow

Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila

August 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is associated with intestinal barrier defects and gut microbiota dysbiosis. The gut commensal bacterium Akkermansia muciniphila (Akk) maintains intestinal barrier integrity and improves MASH-related metabolic syndromes. Berberine (BBR), a traditional Chinese medicine, shows promise in treating MASH. However, research on drugs that target Akk regulation and its underlying mechanisms remains limited. This study investigates the mechanisms by...

Read More arrow

CuSO<sub>4</sub> protects hepatocytes from lipotoxicity by promoting autophagic degradation of lipid droplets to attenuate oxidative stress

August 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a prevalent chronic liver condition that often progresses to Metabolic Dysfunction-Associated Steatohepatitis (MASH), ultimately leading to liver fibrosis and hepatocellular carcinoma (HCC). Consequently, the early diagnosis and treatment of MASLD are particularly crucial. Currently, the pathogenic mechanisms underlying MASLD remain incompletely understood, and there is no optimal therapy available for this condition. The liver...

Read More arrow

Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis

August 2025

Metabolic dysfunction associated steatohepatitis (MASH), formerly known as NASH, represents one of the leading causes of chronic liver disease worldwide. Its high prevalence is driven by insulin resistance, obesity and type 2 diabetes (T2D) and is associated with cardiovascular disease. The main driver of liver damage is fat accumulation in hepatocytes leading to inflammation and fibrosis development. People with MASH and clinically significant fibrosis (stage F2/F3) are 'at risk' of progressing...

Read More arrow

CuSO<sub>4</sub> protects hepatocytes from lipotoxicity by promoting autophagic degradation of lipid droplets to attenuate oxidative stress

August 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a prevalent chronic liver condition that often progresses to Metabolic Dysfunction-Associated Steatohepatitis (MASH), ultimately leading to liver fibrosis and hepatocellular carcinoma (HCC). Consequently, the early diagnosis and treatment of MASLD are particularly crucial. Currently, the pathogenic mechanisms underlying MASLD remain incompletely understood, and there is no optimal therapy available for this condition. The liver...

Read More arrow